ResMed Inc. (RMD) - 10-K Summary
Business Context and Reporting Period
Company: ResMed Inc.
Filing Type: Form 10-K (Annual Report)
Fiscal Year Ended: June 30, 2025
Business Overview: ResMed is a global leader in digital health and cloud-connected medical devices, primarily treating sleep apnea, COPD, and other respiratory disorders. The company operates two segments: Sleep and Breathing Health (devices, masks, diagnostics) and Residential Care Software (cloud-based solutions for healthcare providers). In May 2025, ResMed acquired VirtuOx, an independent diagnostic testing facility, to expand its end-to-end diagnostic and monitoring capabilities.
Key Financial Metrics (Fiscal Year 2025)
| Metric | 2025 (in millions) | 2024 (in millions) |
|---|---|---|
| Net Revenue | $5,146.3 | $4,685.3 |
| Gross Profit | $3,055.0 | $2,655.3 |
| Gross Margin | 59.4% | 56.7% |
| Operating Income | $1,685.4 | $1,319.9 |
| Net Income | $1,400.7 | $1,021.0 |
| Diluted EPS | $9.51 | $6.92 |
| Operating Cash Flow | $1,751.6 | $1,401.3 |
| Cash & Equivalents (End of Period) | $1,209.5 | $238.4 |
| Total Debt (Net) | $668.3 | $707.2 |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 10% year-over-year, driven by increased demand and unit sales in both the Sleep and Breathing Health and Residential Care Software segments. Growth was consistent across U.S. and international markets.
- Margin Expansion: Gross margin improved by 270 basis points to 59.4%, attributed to procurement/manufacturing efficiencies and the absence of $14.3 million in field safety notification expenses recognized in the prior year (related to masks with magnets and Astral devices).
- Profitability: Net income surged 37% to $1.4 billion. This was aided by a decrease in the effective tax rate to 16.5% (from 19.3%), largely due to IRS refunds of interest and penalties and tax benefits from business cessation.
- Debt Reduction: Total debt decreased as the company repaid its revolving credit facility, resulting in a shift from net interest expense of $45.7 million in 2024 to net interest income of $4.1 million in 2025.
- Restructuring: Unlike the prior year, which saw $64.2 million in restructuring charges, ResMed incurred no material restructuring expenses in fiscal 2025.
Guidance, Outlook, and Risks
Management Commentary & Strategy: Management continues to focus on integrating AI and machine learning into products to enhance therapy performance. The company is expanding its diagnostic capabilities following the VirtuOx acquisition and the U.S. launch of the NightOwl home sleep apnea test. Capital allocation remains focused on R&D, strategic acquisitions, share repurchases, and dividends.
Key Risks & Contingencies:
- Regulatory & Reimbursement: Significant uncertainty exists regarding U.S. healthcare policy, including the "One Big Beautiful Bill Act" signed in July 2025, which cuts federal Medicaid funding and alters reimbursement rates. Changes to VA disability ratings for sleep apnea and the reinstatement of Medicare competitive bidding could negatively impact sales.
- Competition: The market faces competition from new pharmaceutical treatments for obesity (GLP-1s) which may reduce the severity of sleep apnea, as well as the potential return of competitor Philips to the U.S. market following a consent decree.
- Supply Chain & Geopolitics: Risks include tariffs, trade restrictions, and supply chain disruptions for raw materials and electronic components (e.g., magnets, semiconductors).
- Legal: Ongoing patent litigation with New York University (NYU) and Cleveland Medical Devices remains a contingency, though recent PTAB rulings have been favorable to ResMed.
Investor Verification Checklist
- Reimbursement Policy Impact: Verify the specific financial impact of the "One Big Beautiful Bill Act" and potential changes to Medicare/Medicaid reimbursement rates on future margins.
- Pharmaceutical Competition: Monitor the adoption rates of GLP-1 weight loss drugs and their correlation with new sleep apnea device prescriptions.
- VirtuOx Integration: Assess the integration progress and revenue contribution of the VirtuOx acquisition, including compliance with Medicare billing requirements.
- Patent Litigation Status: Track the outcome of the NYU patent appeal at the Court of Appeals for the Federal Circuit scheduled for August 2025.
- Supply Chain Resilience: Review updates on the availability and cost of critical components, specifically magnets and semiconductors, given recent trade policy shifts.